Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis--implications for post-transplantation bone disease
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Post-transplantation bone disease is associated with a high degree of morbidity including pain and fractures. Glucocorticoid-induced osteoporosis on top of pre-existing renal osteodystrophy is considered the major pathogenic factor, while the role of non-glucocorticoid immunosuppressants is less well defined. METHODS: In this study, we investigated the influence of sirolimus (SRL) versus calcineurin inhibitor (CI)-based immunosuppressive regimens on biomarkers of bone resorption in renal transplant patients. In addition, the impact of SRL, tacrolimus and mycophenolate mofetil (MMF) on osteoclast activation and function was assessed in cell culture systems. RESULTS: Using this approach, we demonstrated reduced serum levels of bone resorption markers in patients treated with SRL after kidney transplantation compared to a CI-based regimen. In line with this observation, we detected profoundly reduced osteoclast differentiation and subsequently diminished hydroxyapatite resorption in the presence of SRL compared to MMF and tacrolimus in vitro. Moreover, SRL significantly reduced osteoclast precursor proliferation in vitro compared to tacrolimus and led to augmented apoptosis in osteoclast precursors. CONCLUSIONS: Taken together, SRL was shown to inhibit osteoclast formation in vivo and in vitro. SRL thus may have the potential to balance osteoclast promoting effects of glucocorticoids and CI, thereby counteracting the development of accelerated osteoporosis in renal transplant recipients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 1×
“[8].”
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“As shown by the bone phenotypes of knockout mice, the OPG–RANKL–RANK system represents the master switch in osteoclast differentiation [34–36].”
BackgroundOsteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Li, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1566 · Cited by 1,119 · cited 1×
“As shown by the bone phenotypes of knockout mice, the OPG–RANKL–RANK system represents the master switch in osteoclast differentiation [34–36].”
BackgroundRole of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · cited 2×
“Conversely, increased RANKL signalling has been consistently observed in demineralizing diseases with enhanced osteoclast activity in humans [11, 12].”
BackgroundResultMechanisms of Glucocorticoid Action in Bone
CANALIS, E., & DELANY, A. M. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04204.x · Cited by 406 · cited 1×
“Glucocorticoids are both pro-osteopenic and pro-osteolytic in that they reduce osteoblastic cell proliferation and increase osteoclasts via a suppression of OPG as well as an induction of RANKL at the transcriptional level [18, 19].”
BackgroundM-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase
Glantschnig, H., Fisher, J. E., Wesolowski, G., Rodan, G. A., & Reszka, A. A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401285 · Cited by 350
Redlich, K., Görtz, B., Hayer, S., Zwerina, J., Doerr, N., Kostenuik, P., Bergmeister, H., Kollias, G., Steiner, G., Smolen, J. S., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63144-6 · Cited by 134
Cited by
Inflammatory bone loss: pathogenesis and therapeutic intervention
Redlich, K., & Smolen, J. S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3669 · Cited by 830
Anastasilakis, A. D., Tsourdi, E., Makras, P., Polyzos, S. A., Meier, C., McCloskey, E. V., Pepe, J., & Zillikens, M. C. (2019) · Bone · doi:10.1016/j.bone.2019.07.006 · Cited by 71
Lan, G.-B., Xie, X.-B., Peng, L.-K., Liu, L., Song, L., & Dai, H.-L. (2015) · BioMed Research International · doi:10.1155/2015/413169 · Cited by 46
Mechanism and treatment strategy of osteoporosis after transplantation
Song, L., Xie, X.-B., Peng, L.-K., Yu, S.-J., & Peng, Y.-T. (2015) · International Journal of Endocrinology · doi:10.1155/2015/280164 · Cited by 30
Metadata
- Authors
- Westenfeld, R., Schlieper, G., Woltje, M., Gawlik, A., Brandenburg, V., Rutkowski, P., Floege, J., Jahnen-Dechent, W., & Ketteler, M.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-05-28
- Volume
- 26
- Issue
- 12
- Pages
- 4115-4123
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2156329907
- Cited by
- 84
- References
- 8
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis--implications for post-transplantation bone disease. https://app.cochat.ai/papers/10.1093/ndt/gfr214
- The paper
- Westenfeld, R., Schlieper, G., Woltje, M., Gawlik, A., Brandenburg, V., Rutkowski, P., Floege, J., Jahnen-Dechent, W., & Ketteler, M. (2011). Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis--implications for post-transplantation bone disease. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfr214
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.